Barnes Labs launches light technology targeting Alzheimer’s-causing bacteria, promising improved cognitive function.
—
Barnes Labs announces a significant advancement in Alzheimer's research by introducing its light technology. This innovative treatment is designed to target and eliminate the bacteria Porphyromonas gingivalis (P. Gingivalis), believed to contribute to the neurodegenerative process of Alzheimer's disease by causing amyloid plaques in the brain.
Barnes Labs is currently preparing to extend its trials and is seeking volunteers with early-stage dementia to participate in further testing
Alzheimer’s disease affects millions globally, leading to cognitive decline and memory loss. Traditional treatments have largely focused on symptom management without addressing the root causes of the disease. Barnes Labs' approach, however, utilizes a patent-pending Phototherapy
technology that targets the bacterial pathogens associated with the formation of amyloid plaques.
The technology operates by emitting a specific frequency of light that penetrates the brain tissue and disrupts the DNA of P. Gingivalis bacteria, effectively destroying the bacteria on contact. This method not only prevents the formation of new plaques but also reduces the overall bacterial load, potentially halting the progression of the disease and possibly even reversing its effects.
Early clinical trials and case studies have demonstrated promising results. Participants receiving light therapy showed marked improvements in cognitive function, and a significant reduction in neuro-inflammation was observed. Notably, one case study highlighted an elderly patient whose hand tremors ceased after just 30 minutes of treatment, showcasing the potential immediate impact of this technology.
"As we advance in our clinical trials, we are optimistic about the potential of light therapy as a transformative treatment for Alzheimer's patients," said a spokesperson for Barnes Labs. "This technology is not only non-invasive and targeted but also free from the side effects commonly associated with conventional drug treatments."
Barnes Labs is currently preparing to extend its trials and is seeking volunteers with early-stage dementia to participate in further testing. This next phase is crucial for validating the efficacy and safety of the treatment on a broader scale.
Barnes Labs is committed to pushing the boundaries of medical science to find viable solutions for one of the most challenging diseases of our time. The technology is highly proprietary and can only be revealed by signing an NDA/non-compete agreement.
If you are interested in getting more information about Barnes Labs' research, or to participate in upcoming trials, please visit https://www.barnes-labs.com.
About Barnes Labs:
Founded with the mission to innovate within the neuroprotective therapy space, Barnes Labs is dedicated to developing technologies that offer new hope to patients suffering from neurodegenerative diseases. Our commitment to research excellence and patient care positions us at the forefront of medical breakthroughs in the treatment of Alzheimer's disease.
Media Contact:
Frank Rossani
media@barnes-labs.com
718-872-5010
Contact Info:
Name: Mike Barnes
Email: Send Email
Organization: Barnes Labs
Phone: 352-615-0765
Website: https://www.barnes-labs.com
Release ID: 89134804
Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.
